| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | -0.014 | 0.9 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | 0.0079 | 0.9 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.0076 | 0.9 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.0082 | 0.9 |
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | 0.0084 | 0.9 |
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | -0.0073 | 0.9 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.9 |
| mRNA | carboplatin:UNC0638 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0072 | 0.9 |
| mRNA | BYL-719 | CTRPv2 | pan-cancer | AAC | 0.0083 | 0.9 |
| mRNA | blebbistatin | CTRPv2 | pan-cancer | AAC | 0.013 | 0.9 |